Text Size

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2

This study has been completed.
Sponsor:
Collaborator:
Yale University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000319
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: June 1996
History of Changes
  Purpose

The purpose of this study is to evaluate the efficacy of treating opioid-dependent individuals with buprenorphine on a thrice-weekly schedule compared to daily dosing.


Condition Intervention Phase
Opioid-Related Disorders
Substance-Related Disorders
 Drug: Buprenorphine
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Buprenorphine Maintenance Dose Schedule and Treatment Setting

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Withdrawal symptoms
  • Opioid and cocaine use
  • Social and psychological functioning
  • AIDS risk behavior
  • Opiate withdrawal symptoms

Estimated Enrollment: 0
Study Start Date: June 1996
  Eligibility

Ages Eligible for Study:   21 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000319

Locations
United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Yale University
Investigators
Principal Investigator: Richard Schottenfeld, M.D. Yale University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000319     History of Changes
Other Study ID Numbers: NIDA-09803-2, R01-09803-2
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on June 18, 2013